Posted On: 03/02/2015 8:53:58 PM
Post# of 30034
Longboard: I believe AMBS patents only cover "recombinant MANF" on indications that we've done enough preclinical studies on to justify applying for a patent. (The Eye Franchise, Parkinsons, Diabetes/Wolframs/ TBI, Ischemic Heart, etc.)
We only have a claim on the indications we've secured a patent on. Our claim on MANF is not limitless.
So if Roche filed a patent on an indication that we didn't apply for first....we have no claim on their use of MANF...even if they're using recombinant MANF.
Small molecules that target endogenous MANF production within the body have nothing to do with AMBS. (Urano currently is preferring that method over recombinant on wolframs. He will use recombiniant MANF on the eye damaged by diabetes)
Many people here think every time the word MANF is used in an article that it is going to automatically put money in our pockets. Not true.
Not to worry. The Eye Franchise is huge enough with retinitis and glaucoma, and macular degeneration....that we really don't need any other indications....if the Eye Franchise pans out.
We only have a claim on the indications we've secured a patent on. Our claim on MANF is not limitless.
So if Roche filed a patent on an indication that we didn't apply for first....we have no claim on their use of MANF...even if they're using recombinant MANF.
Small molecules that target endogenous MANF production within the body have nothing to do with AMBS. (Urano currently is preferring that method over recombinant on wolframs. He will use recombiniant MANF on the eye damaged by diabetes)
Many people here think every time the word MANF is used in an article that it is going to automatically put money in our pockets. Not true.
Not to worry. The Eye Franchise is huge enough with retinitis and glaucoma, and macular degeneration....that we really don't need any other indications....if the Eye Franchise pans out.
(0)
(0)Scroll down for more posts ▼
